Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closed to Accrual

Canadian Cancer Trials Group IND.177 -- A Phase I Study of AT7519M Given Twice Weekly in Patients with Advanced Incurable Malignancy - was closed to accrual on 4 April 2011 after establishing the recommended phase II dose (RP2D), as per protocol.